Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. [electronic resource]
Producer: 20110727Description: 1708-15 p. digitalISSN:- 1476-5454
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Double-Blind Method
- Female
- Fovea Centralis -- pathology
- Humans
- Intravitreal Injections
- Macular Degeneration -- drug therapy
- Male
- Middle Aged
- Prospective Studies
- Ranibizumab
- Visual Acuity -- physiology
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.